Generex Biotechnology Corporation (NASDAQ: GNBT), a biopharmaceutical company, has a diversified product portfolio designed to deliver innovative products to treat patients with cancer. DNA/RNA-based Medicines and Small Molecules are the two major programs that anchor the Company’s research platform. Ganite® (gallium nitrate injection) is the company’s leading drug in the Small Molecule program. Ganite is exclusively marketed in the U.S. to treat symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. For further information, visit the Company’s web site at www.genta.com.
- 17 years ago
QualityStocks
Generex Biotechnology Corporation (NASDAQ: GNBT)
Tags Rodman & Renshaw
Related Post
-
HeartBeam Inc. (NASDAQ: BEAT) Is ‘One to Watch’
HeartBeam has developed the first cable-free system capable of synthesizing a 12-lead ECG from 3D,…
-
Platinum Group Metals Ltd. (NYSE American: PLG) (TSX: PTM) Poised to Capitalize on Rising Platinum, Palladium Prices Amid Renewed Demand
Platinum prices have recently reached their highest levels in more than two years. Palladium has…
-
QualityStocksNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Forms Investor Relations Partnership With astr Partners
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, and its subsidiary HOPE Therapeutics announced a…